维生素在精神病研究:B12、B6和叶酸对首发精神病症状与神经认知的随机双盲安慰剂对照试验
这项随机双盲安慰剂对照试验纳入120例首发精神病患者,评估辅助补充叶酸(5 mg)、B12(0.4 mg)和B6(50 mg)每日一次共12周对症状和神经认知的影响。结果显示B族维生素显著降低同型半胱氨酸(p = .003,效应量 = -0.65),但对PANSS总分(p = .749)和复合神经认知(p = .785)无显著影响;注意力/警觉域组间差异显著(p = .024,效应量 = 0.49),B族维生素组保持稳定而安慰剂组下降。基线同型半胱氨酸升高(占样本14%)、情感性精神病和女性与部分神经认知域改善相关,遗传变异未影响治疗反应。
要点
- B族维生素显著降低同型半胱氨酸,但未改善PANSS总分或复合神经认知。
- 注意力/警觉域组间差异显著,B族维生素组稳定而安慰剂组下降。
- 基线同型半胱氨酸升高、情感性精神病和女性与部分神经认知改善相关。
核心结论
- 12周B族维生素补充可能不改善整体精神病理学和全局神经认知,但在注意力/警觉方面可能具有特定神经保护特性。
- 结果支持在首发精神病中采用个性化维生素补充方法。
研究设计与样本
- 随机、双盲、安慰剂对照试验。
- 共120例首发精神病患者随机分配至辅助B族维生素补充剂(含叶酸5 mg、B12 0.4 mg、B6 50 mg)或安慰剂,每日一次,共12周。
主要发现
- B族维生素补充降低同型半胱氨酸水平(p = .003,效应量 = -0.65)。
- B族维生素补充对PANSS总分(p = .749)或复合神经认知(p = .785)无显著影响。
- 次要症状域无显著组间差异。
- 注意力/警觉域组间差异显著(p = .024,效应量 = 0.49),B族维生素组保持稳定而安慰剂组表现下降。
- 14%的样本基线同型半胱氨酸升高,与B族维生素补充后注意力/警觉某一测量指标的更大改善相关;女性和情感性精神病与B族维生素补充后选择域神经认知改善相关;遗传变异未影响B族维生素治疗反应。
关键数值与推荐
- B族维生素补充剂含叶酸5 mg、B12 0.4 mg、B6 50 mg,每日一次,共12周。
- 共同主要结局为PANSS总分变化和复合神经认知变化。
临床怎么用
- 在首发精神病中,B族维生素补充可能对注意力/警觉有特定益处,尤其对基线同型半胱氨酸升高、情感性精神病和女性患者。
- 支持基于个体特征(同型半胱氨酸水平、性别、诊断亚型)的个性化维生素补充策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Elevated homocysteine is observed in schizophrenia and associated with illness severity. The aim of this study was to determine whether vitamins B12, B6, and folic acid lower homocysteine and improve symptomatology and neurocognition in first-episode psychosis. Whether baseline homocysteine, genetic variation, sex, and diagnosis interact with B-vitamin treatment on outcomes was also examined. METHODS: A randomized, double-blind, placebo-controlled trial was used. A total of 120 patients with first-episode psychosis were randomized to an adjunctive B-vitamin supplement (containing folic acid [5 mg], B12 [0.4 mg], and B6 [50 mg]) or placebo, taken once daily for 12 weeks. Coprimary outcomes were change in total symptomatology (Positive and Negative Syndrome Scale) and composite neurocognition. Secondary outcomes included additional measures of symptoms, neurocognition, functioning, tolerability, and safety. RESULTS: B-vitamin supplementation reduced homocysteine levels (p = .003, effect size = -0.65). B-vitamin supplementation had no significant effects on Positive and Negative Syndrome Scale total (p = .749) or composite neurocognition (p = .785). There were no significant group differences in secondary symptom domains. A significant group difference in the attention/vigilance domain (p = .024, effect size = 0.49) showed that the B-vitamin group remained stable and the placebo group declined in performance. In addition, 14% of the sample had elevated baseline homocysteine levels, which was associated with greater improvements in one measure of attention/vigilance following B-vitamin supplementation. Being female and having affective psychosis was associated with improved neurocognition in select domains following B-vitamin supplementation. Genetic variation did not influence B-vitamin treatment response. CONCLUSIONS: While 12-week B-vitamin supplementation might not improve overall psychopathology and global neurocognition, it may have specific neuroprotective properties in attention/vigilance, particularly in patients with elevated homocysteine levels, patients with affective psychosis, and female patients. Results support a personalized medicine approach to vitamin supplementation in first-episode psychosis.
引用
- Allott K, McGorry PD, Yuen HP, et al. The Vitamins in Psychosis Study: A Randomized, Double-Blind, Placebo-Controlled Trial of the Effects of Vitamins B12, B6, and Folic Acid on Symptoms and Neurocognition in First-Episode Psychosis. Biol Psychiatry. 2019. PMID: 30771856. doi:10.1016/j.biopsych.2018.12.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。